Human immunodeficiency virus (HIV) attacks the body’s immune system, leading to complete damage of the system and making the host system susceptible to infection. The virus attacks the CD4 cells, whose primary role is to help the immune system defend infections, thus destroying the first line of defense of the human body and exposing the person to various infections. HIV is one of the most alarming and widespread diseases globally. The major route of transmission of HIV infection is through unprotected sex, use of contaminated needles, breast milk of HIV-infected mother to child, and infected blood.
The global HIV drugs market is bifurcated into medication class and region. On the basis of medication class, the market is classified into multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), nonOnucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), entry inhibitors, and HIV integrase strand transfer inhibitors. In the medication class, the multi-class combination drugs segment holds the largest market share as it involves the most advanced technique used for the treatment of HIV infection. Furthermore, this is attributed to the increase in adoption of drugs from this medication class, owing to their better results in the control of HIV & related co-infections and their ease in consumption & adherence.
Based on region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the largest market share in 2015, owing to increase in the number of HIV-infected individuals, advancement in HIV treatment, and rise in government funding for R&D for drug manufacturing. In addition, Asia-Pacific is expected to emerge with the maximum growth potential due to the focus of key players on emerging economies, mainly on the health of people with effective treatment for different diseases and rise in incidence of HIV infection.
The report provides a comprehensive analysis of key players that operate in the HIV drugs market such as Boehringer Ingelheim International GmbH, Merck & Co., Inc., Pfizer Inc., Gilead Sciences, Inc., GalaxoSmithKline plc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., AbbVie, and Cipla.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides in-depth analysis of the market along with the current trends and future estimations to explain the imminent investment pockets.
- The report offers a quantitative analysis from 2019 to 2027, which is expected to enable stakeholders to capitalize on the prevailing market opportunities.
- The key market players and their strategies have been analyzed to understand the competitive outlook of the market.
Key market segments
By Medication Class
- Multi-class Combination Drugs
- Atripla
- Complera
- Prezcobix/Prezista
- Stribild
- Genvoya
- Odefsey
- Symtuza
- Triumeq
- Descovy
- Others
- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Emtriva
- Epivir
- Epzicom
- Truvada
- Biktarvy
- Others
- NonOnucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- Edurant
- Others
- Protease Inhibitors(PIs)
- Aptivus
- Kaletra
- Lexiva
- Norvir
- Viracept
- Others
- Entry Inhibitors
- Selzentry
- HIV Integrase Strand Transfer Inhibitors
- Isentress
- Tivicay
By Region
North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
List of key players profiled in the report
- Boehringer Ingelheim International GmbH
- Merck & Co., Inc.
- Pfizer Inc.
- Gilead Sciences, Inc.
- GalaxoSmithKline plc. (ViiV Healthcare)
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd.
- Teva Pharmaceutical Industries Ltd.
- AbbVie
- Cipla
Table of Contents
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...